Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes
- 22 November 2002
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cancer Gene Therapy
- Vol. 9 (12), 1022-1035
- https://doi.org/10.1038/sj.cgt.7700542
Abstract
Oncolytic viruses are attractive therapeutics for cancer because they selectively amplify, through replication and spread, the input dose of virus in the target tumor. To date, clinical trials have demonstrated marked safety but have not realized their theoretical efficacy potential. In this review, we consider the potential of armed therapeutic viruses, whose lytic potential is enhanced by genetically engineered therapeutic transgene expression from the virus, as potential vehicles to increase the potency of these agents. Several classes of therapeutic genes are outlined, and potential synergies and hurdles to their delivery from replicating viruses are discussed.Keywords
This publication has 120 references indexed in Scilit:
- Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgeneCancer, 2002
- Oncolytic biotherapy: a novel therapeutic platformThe Lancet Oncology, 2002
- Replicating adenoviral vector–mediated transfer of a heat-inducible double suicide gene for gene therapyCancer Gene Therapy, 2001
- Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regressionGene Therapy, 2000
- Use of Newcastle Disease Virus Vaccine (MTH-68/H) in a Patient With High-grade GlioblastomaJAMA, 1999
- Thymidine Kinase-Deleted Vaccinia Virus Expressing Purine Nucleoside Phosphorylase as a Vector for Tumor-Directed Gene TherapyHuman Gene Therapy, 1999
- A Novel Multiply-Mutated HSV-1 Strain for the Treatment of Human Brain TumorsHuman Gene Therapy, 1997
- Cytotoxic T-cell-derived granzyme B activates the apoptotic protease ICE-LAP3Current Biology, 1996
- Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinial relevanceImmunology Today, 1995
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990